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WriteClick:
Editor’s Choice
A RANDOMIZED TRIAL OF VARENICLINE
(CHANTIX) FOR THE TREATMENT OF
SPINOCEREBELLAR ATAXIA TYPE 3
Alessandro Filla, Francesco Sacca, Giuseppe De
Michele, Napoli, Italy: Zesiewicz et al.1 reported
that varenicline improved ataxia in patients with
spinocerebellar ataxia type 3 (SCA3), yet the follow-
ing issues should be considered.
1. Why did the authors use the Fisher test for com-
parison of baseline characteristics (table 1)? Pa-
tients in the placebo group appeared to be older
and more severely compromised. For this reason,
wouldn’t the subjects respond less to treatment?
Blocked randomization may have prevented un-
equal distribution between groups.
2. The number of patients was small. Furthermore,
due to the large number of dropouts in the placebo
group, the authors could not complete the originally
planned crossover study. This weakens the study
and its results. Power calculation, which also ac-
counts for patient dropout, was not performed.
3. Primary efficacy measures included all the SARA
subscores and there were no corrections made for
multiple comparisons. The SARA subscore for
gait improved more in the varenicline group (ta-
ble 21), but stance improved more in the placebo.
Can the authors explain this discrepancy? In con-
trolled trials, it is preferable to choose a priori a
single, major study endpoint.
4. Beck Anxiety Inventory score improved in the va-
renicline group. Could mood improvement con-
tribute to better performance for SARA?
This article contributes to the study of degenera-
tive ataxias where effective treatments are lacking and
new strategies are needed. However, the results of the
study should be taken cautiously. This trial might be
considered more a safety trial than a study on effi-
cacy. Results of drug efficacy should be obtained in a
larger study that complies with the guidelines of a
well-designed, controlled, randomized trial.
Copyright © 2012 by AAN Enterprises, Inc.
1. Zesiewicz TA, Greenstein MB, Sullivan KL, et al. A random-
ized trial of varenicline (Chantix) for the treatment of spino-
cerebellar ataxia type 3. Neurology 2012;78:545–550.
ROLE OF DATSCAN AND CLINICAL
DIAGNOSIS IN PD
Nin P.S. Bajaj, Nottingham, UK: The authors dis-
cuss the role of DaTSCAN and paint a rosy picture
of clinical diagnostic accuracy in PD.1 Clinicopatho-
logic studies2 suggest good diagnostic accuracy in PD
yet experience from drug trials suggests a PD diagno-
sis error rate of up to 15% and community studies an
error rate of over 50%.3 A recent blinded video study
showed high false-positive and false-negative error
rates in PD diagnosis and poor concordance between
movement disorder experts, which illustrates the fra-
gility and subjectivity of clinical diagnosis in tremu-
lous patients.3 The indication of DaTSCAN is not
for diagnosis of PD or parkinsonian syndromes but
per US Food and Drug Administration prescribing
information is “for visualization of the dopamine
transporter (DaT) distribution within the striatum . . .
to assist in the evaluation of adult patients with sus-
pected parkinsonian syndromes.”4 Only a clinician
canmake a diagnosis. DaTSCANmay enable that diag-
Editors’ Note: A common argument offered to medical
students in favor of pursuing a career in neurology is
that it is among the rare specialties in which the
examination still must guide the imaging. There is no
magic bullet of neuroradiologic tests; no one study
every patient must have before the neurologist even
sets eyes on them. This edict comes to mind as author
Dr. de la Fuente-Fernandez and WriteClick contributor Dr.
Bajaj debate the role of DaTSCAN, a radioisotope used in
combination with SPECT imaging to view the striatal
dopaminergic system, as an aid in the diagnosis of
Parkinson disease (PD). Dr. Bajaj argues that PD clinical
diagnostic accuracy and concordance between specialists is
lower than reported and that DaTSCAN may be useful in
challenging patients. Dr. de la Fuente-Fernandez counters
that the radiation risk may be too great for a test that
benefits the doctor more than the patient.
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